© 2004 by European Society of Cardiology
Copyright © 2004, European Society of Cardiology
Inhibition of the activation of nuclear factor kappa B to reduce myocardial reperfusion injury and infarct size
Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, John-Vane Science Centre, Barts and the Royal London School of Medicine and Dentistry, Charterhouse Square, London EC1M6BQ, UK
*Tel.: +44-207-9826199l; fax: +44-207-2511685. Email address: c.thiemermann@qmul.ac.uk
Received 30 March 2004; revised 21 April 2004; accepted 22 April 2004
| The first 10% of the full text of this article appears below. |
See article by Onai et al. [6] (pages 51–59) in this issue.
Nuclear factor kappa B (NF-
B) is a transcription factor that plays a pivotal role in the induction of genes involved in physiological processes as well as in the response to injury and inflammation. The process leading to the activation of NF-
B requires phosphorylation of an inhibitor of NF-
B (I
B) by I
B kinase (IKK), resulting in degradation of I
B by the 26S proteasome. This allows the translocation of NF-
B from the cytosol to the nucleus, where the heterodimer binds to a response element in the promotor region of specific target genes. Activation of NF-
B induces gene programs leading to the transcription of factors that promote inflammation (i.e. adhesion molecules, cytokines